武田认为利斯波西顿治疗发作性睡病的后期积极结果

2025-07-14 20:47

Takeda Pharmaceutical (NYSE:TAK) said that data from two phase 3 trials on oveporexton for narcolepsy type 1 met all of its primary and secondary endpoints.
The stock is up ~3% in pre-market trading Monday.
Oveporexton, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, demonstrated significant improvement in excessive daytime sleepiness measured by the Maintenance of Wakefulness Test, meeting the primary endpoint.
Secondary endpoints in the FirstLight and RadiantLight trials included improvement in excessive daytime sleepiness measured by the Epworth Sleepiness Scale and in the Weekly Cataplexy Rate.
Narcolepsy type 1 is caused by the loss of orexin-producing neurons in the brain.
Takeda said it plans to submit an NDA to the U.S. FDA as well as other regulatory bodies by the end of fiscal year 2025.

More on Takeda Pharmaceutical